That data suggests that evaluation of circulating IGF1, together with the proinflammatory markers, might be useful to assess the severity of the NAFLD and can be target for novel form of NAFLD therapeutic strategy. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.